In numerous basic and clinical studies, the combination of anti-vascular targeting drugs with PD-1/PD-L1 antibodies has demonstrated notably synergistic antitumor effect in a variety type of cancer [24–28]. This evidence concerns the gene PDCD1 and cancer.